ELANCO ANIMAL HEALTH INCORPORATED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.7 USD | -1.76% |
|
-2.17% | +12.08% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 4.49B 6.13B | Sales 2025 * | 4.69B 6.4B | Capitalization | 8.25B 11.27B |
|---|---|---|---|---|---|
| Net income 2024 * | -27M -36.87M | Net income 2025 * | 52M 71.01M | EV / Sales 2024 * | 2.9 x |
| Net Debt 2024 * | 4.77B 6.52B | Net Debt 2025 * | 4.28B 5.84B | EV / Sales 2025 * | 2.67 x |
| P/E ratio 2024 * |
-398
x | P/E ratio 2025 * |
70.1
x | Employees | 9,550 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.34% |
More Fundamentals
* Assessed data
More news
Latest transcript on Elanco Animal Health Incorporated
More recommendations
More press releases
| 1 day | -1.76% | ||
| 1 week | -2.17% | ||
| Current month | +26.90% | ||
| 1 month | +28.96% | ||
| 3 months | +3.34% | ||
| 6 months | +41.77% | ||
| Current year | +12.08% |
1 week
16.65
17.42
1 month
12.7917.43
Current year
12.6917.43
1 year
7.8817.43
3 years
7.8837.49
5 years
7.8837.49
10 years
7.8837.61
| Managers | Title | Age | Since |
|---|---|---|---|
Jeffrey Simmons
CEO | Chief Executive Officer | 56 | 18-06-30 |
Todd Young
DFI | Director of Finance/CFO | 52 | 18-12-13 |
| Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Bill Doyle
BRD | Director/Board Member | 61 | 20-12-13 |
Art Garcia
BRD | Director/Board Member | 63 | 19-05-07 |
John Bilbrey
BRD | Director/Board Member | 67 | 19-03-10 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 13.88% | 254 M€ | +11.80% | - | |
| 10.49% | 1 M€ | -.--% | ||
| 0.35% | 17 M€ | +8.99% | - | |
| 0.33% | 2 M€ | +10.04% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-21 | 16.7 | -1.76% | 3,161,292 |
| 24-05-20 | 17 | -1.11% | 3,431,012 |
| 24-05-17 | 17.19 | +1.24% | 5,540,367 |
| 24-05-16 | 16.98 | -0.35% | 2,414,516 |
| 24-05-15 | 17.04 | -0.18% | 4,279,415 |
Delayed Quote Nyse, May 21, 2024 at 04:00 pm
More quotes
Elanco Animal Health Incorporated is an animal health company. The Company is focused in delivering products and services to prevent and treat disease in farm animals and pets. Its portfolio serves animals across its core species consisting of dogs, cats and cattle, poultry, swine, sheep and aqua. It offers products in two primary categories: Pet Health and Farm Animal. Its Pet Health portfolio is focused on parasiticides, vaccines and therapeutics. Its Pet Health portfolio products that protect pets from fleas, ticks and internal parasites. Its Farm Animal portfolio of products is primarily focused on cattle, swine, poultry, and aquaculture. Its Pet Health products include Advantage Family, Atopica, Claro/ Neptra, Credelio Family, Drontal Family, Galliprant, Interceptor Plus, Milbemax, Onsior, Seresto, Trifexis, and TruCan. Its Farm Animal products include AviPro, Baycox, Catosal, Comforta, Denagard, Experior, Hemicell, Maxiban, Monteban, Pulmotil, Rumensin, and others.
Sector
Pharmaceuticals
Calendar
2024-05-30
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
16.7
USD
Average target price
19.11
USD
Spread / Average Target
+14.46%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +12.08% | 8.25B | |
| -12.45% | 78.84B | |
| +25.88% | 3.73B | |
| -0.42% | 3.26B | |
| +15.88% | 1.65B | |
| +0.56% | 1.67B | |
| -17.79% | 1.38B | |
| -0.39% | 1.31B | |
| -5.20% | 1.24B | |
| +6.40% | 1.15B |
- Stock Market
- Equities
- ELAN Stock